Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated2

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated250%

completed125%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_1

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

NCT02398604

withdrawnphase_1

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

NCT03058068

terminatedphase_1

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

NCT02675556

completedphase_1

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

NCT01087996

Clinical Trials (4)

Showing 4 of 4 trials

NCT02398604Phase 1

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Terminated

NCT03058068Phase 1

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

Withdrawn

NCT02675556Phase 1

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Terminated

NCT01087996Phase 1

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4